Breast Cancer Survival in Cameroon: Analysis of a Cohort of 404 Patients at the Yaound&amp;#233; General Hospital

Ngowa, Jean Dupont Kemfang; Kasia, Jean Marie; Yomi, J; Nana, Achille Nkigoum; Ngassam, Anny; Domkam, Irenée; Sando, Zacharie; Ndom, Paul

doi:10.4236/abcr.2015.42005

Cited by 24 publications

(32 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous data showed that the 5-year mortality was from 36% to 38% in Sub-Saharan Africa [22]- [24]. The overall survival and disease-free survival 57.9% and 64.3% respectively are similar to other previous studies performed in the developing countries [25]- [29] ( Table 4).…”

Section: Discussionsupporting

confidence: 86%

Prognosis of Breast Cancer Patients Underwent Surgery in a Developing Country

Traoré¹,

Touré²,

Sy³

et al. 2015

JCT

View full text Add to dashboard Cite

Background: We aim to review different factors associated with the relapse and the mortality in breast cancer patients in restricted-resource settings over a five-year period. Method: A retrospective cohort study including 133 women underwent breast cancer surgery was performed at the Surgical Oncology Unit of the Conakry University Hospital in Guinea. Socio-demographical characteristics, clinical information, treatment and data on relapse and survival were retrieved from medical files. Predictor factors of relapse were analyzed by using univariate and multivariate logistic regression. Factors associated with mortality were analyzed by Kaplan Meier survival and Cox models. Results: Breast cancer surgery was conservative in 13 cases (9.8%) and radical in 120 cases (90.2%). Five-year relapse was 33.8% ± 8.0% and the predictor factors of this relapse were age and stage III (p = 0.005). The overall 5-year mortality was 42.1% and the risk factors independently associated with death were body mass index (p = 0.01), origin of patients (p = 0.02), radiotherapy (p = 0.01) and cancer relapse (p = 0.001). Conclusion: The proportions of relapse and death were higher in breast cancer patients. The age and the stage of cancer at the time of surgery were the predictor factors of relapse. Body mass index, origin of patients, radiotherapy and cancer relapse were associated with death.

show abstract

Section: Discussionsupporting

confidence: 86%

Prognosis of Breast Cancer Patients Underwent Surgery in a Developing Country

Traoré¹,

Touré²,

Sy³

et al. 2015

JCT

View full text Add to dashboard Cite

show abstract

“…In our study, the overall median survival for histologically confirmed breast cancer was 56.5(95% CI, 53.46 -60.83) months. Our results were higher than the previous studies in which the median survival was 24 months in Cameroon (25),40 months in Sudan (30) ,but lower than to the result reported from Malaysia the median survival was 68.1 months (23). Although, our study showed higher overall median survival than that seen in the Cameroon and Sudan studies, the lower value obtained in comparison with Malaysia is most probably due to shorter period of study in ours.…”

Section: Discussioncontrasting

confidence: 91%

“…This finding is in contrary with studies done in different Africa and Asian countries (25,27,33).Which identified breast-conserving surgery, have better survival than mastectomy.…”

Section: Discussioncontrasting

confidence: 91%

Survival status and predictors of mortality among Breast Cancer patients in Adult Oncology Unit at Black Lion Specialized Hospital, Addis Ababa, Ethiopia, 2018

Shiferaw

Mulugeta

Areri

et al. 2019

Preprint

View full text Add to dashboard Cite

Introduction:Breast cancer is a leading cause of death worldwide, and ranks as the fifth cause of death from all cancers, and the most common cause of cancer death in women in both developing and developed countries. Breast cancer ranks as the first most frequent cancer among women in Ethiopia. In spite of the high incidence and mortality rate, survival status among breast cancer patients was not determined in our country. Hence, this study aimed to assess survival status and predictor of mortality among breast cancer patients in Black Lion Specialized Hospital.Objective: the main aim of the study is to assess the survival status and predictor of mortality among Breast Cancer patients in Black Lion Specialized Hospital Adult Oncology Unit in 2018. Methods: An institution based retrospective longitudinal study was conducted in BLSH AdultOncology Unit. All cases of breast cancer registered from January1 st 2012-December30 th , 2014 in BLSH were followed retrospectively for the six-year survival (until december30 th , 2017).Kaplan-meier survival curve together with log rank test were used to test for the presence of difference in survival among predictor variables. Cox regression were used at 5% level of significance to determine the net effect of each explanatory variable on time to death after diagnosis of breast cancer. Results:In this study incidence of mortality was 9.8 per 100 person years (95% CI: 8.49-11.47).The overall median survival time was 56.5(95% CI (53.46 -60.83)) months. The overall estimated survival rate after diagnosis of breast cancer was nearly 27% (95% CI, 17.09 to 36.67 %) at 72 months of follow up. The overall survival rates at 1, 3, and 5 years were, 97.2%, 80.8%, and 46.2% respectively. Predictors of mortality were clinical stage (III&IV),(AHR =1.86), poorly differentiated histology (AHR: 3.

show abstract

“…In Cameroon appropriately, the median survival rate after five years is still weak (around 40%) as compared with developed countries. In addition, 57.9% of breast cancer patients are under 50 years, and 28.5% are less than 40 years [ 17 ]. Due to the high frequency with which breast cancer reaches the human population, the quest for effective and less expensive medical treatment becomes a serious need.…”

Section: Discussionmentioning

confidence: 99%

Abyssinone V‐4’ Methyl Ether Isolated from Erythrina droogmansiana (Leguminosae) Inhibits Cell Growth and Mammary Glands Hyperplasia Induced in Swiss Mice by the 7,12‐Dimethylbenz(a)anthracene

Tueche

Zingue

Tchoupang

et al. 2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

There is a long standing interest in the identification of medicinal plants and derived natural products for developing cancer therapeutics. The present study was designed to evaluate the in vitro and in vivo antiproliferative effects of Abyssinone V-4' methyl ether (AVME) on breast tissue of mice. The cytotoxicity of AVME was evaluated using MTT assay in four cancer cell lines (DU145, PC3, HepG2, and MCF-7). Further, a protective effect of AVME was evaluated on 7,12-dimethylbenz(a)anthracene- (DMBA-) induced breast tumor in Swiss mice. Incidence, burden, volume, and histological analysis of mammary tumors were measured. As a result, AVME inhibits DU145, PC3, HepG2, and MCF-7 cells growth. In vivo, no tumor was detected in mice from the normal group as compared to those of DMBA group. Moreover, AVME inhibits the DMBA-induced mammary glands hyperplasia in mice at the dose of 10 mg/kg, evidenced by a decrease of tumor incidence, tumor weight, and volume as well as a protective effect against the lobular alveolar hyperplasia. Taken all together, these results suggest that Abyssinone V-4' methyl ether is endowed with antitumor properties and could be a source of traditional medicine which deserves to be more elucidated and explored in the foreseeable future.

show abstract

Breast Cancer Survival in Cameroon: Analysis of a Cohort of 404 Patients at the Yaoundé General Hospital

Cited by 24 publications

References 16 publications

Prognosis of Breast Cancer Patients Underwent Surgery in a Developing Country

Prognosis of Breast Cancer Patients Underwent Surgery in a Developing Country

Survival status and predictors of mortality among Breast Cancer patients in Adult Oncology Unit at Black Lion Specialized Hospital, Addis Ababa, Ethiopia, 2018

Abyssinone V‐4’ Methyl Ether Isolated from Erythrina droogmansiana (Leguminosae) Inhibits Cell Growth and Mammary Glands Hyperplasia Induced in Swiss Mice by the 7,12‐Dimethylbenz(a)anthracene

Contact Info

Product

Resources

About